Health Condition 1: J069- Acute upper respiratory infection,unspecified
Conditions
Interventions
Intervention1: Kuka Cough Syrup: Ingredients: Tulsi (Occimum sanctum), Vasaka (Adhatoda vasica), Kulanjana (Alpinia galangal), Yastimadhu (Glycyrrhiza glabra), Pippali (Piper longum) and Sat Pudina (M
Sponsors
Multani Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: History of acute nonproductive cough due to any cause. Subjects who are willing to give informed consent and ready to comply with the protocol. Subjects who are ready to provide regular follow up until the completion of the study.
Exclusion criteria
Exclusion criteria: Participants with a history of acute lower respiratory tract infections such as pneumonia, bronchitis whooping cough, chronic obstructive pulmonary disease/asthma, tuberculosis, systemic bacterial infections for which specific drug therapy required Any underlying lung pathology such as lung abscess or cystic fibrosis, individuals with a history of myocardial infarction within 4 weeks prior to enrollment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VCD scaleTimepoint: Day 0 and 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to relief from cough and throat irritation for all the first morning doses, duration of relief from symptoms for all first morning doses in all the subjects, drowsiness, and Physicianâ??s Global Assessment of efficacy evaluated at visit 4 in both the treatment groups on VCD scalesTimepoint: 14 days | — |
Countries
India
Contacts
Public ContactDr Sanjay Kumar
Multani Pharmaceuticals Ltd. New Delhi
Outcome results
None listed